Semax — BDNF induction, ACTH fragment pharmacology, and the cognitive enhancement mechanism

Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) based on the ACTH 4-10 fragment of adrenocorticotropic hormone. ACTH is best known for stimulating cortisol release from the adrenal cortex, but the 4-10 fragment produces no cortisol stimulation — it exerts its effects entirely within the CNS. The heptapeptide extension adds a C-terminal Pro-Gly-Pro sequence that substantially extends the half-life of the active fragment, enabling meaningful CNS exposure after intranasal administration.

Semax emerged from the same Soviet-era research program that produced Selank, developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. It has been used in Russian clinical settings for stroke rehabilitation and cognitive impairment, which gives it a more substantial human data foundation than most research peptides, albeit outside the Western regulatory trial framework.

The ACTH fragment mechanism

ACTH 4-10 acts through melanocortin receptors — the same receptor family that alpha-MSH and PT-141 engage. Specifically, it binds MC4R in the CNS, which is expressed throughout the hippocampus, cortex, and hypothalamus. MC4R activation in these regions modulates attention, memory formation, and the consolidation of learned behaviours.

Rodent studies with ACTH fragment analogues consistently show enhanced performance in spatial memory tasks, faster maze learning, and improved performance on attention-demanding paradigms. The mechanism involves increased activity in the hippocampal and cortical circuits that support working memory and attention — consistent with MC4R's known role in cognitive processing.

The C-terminal Pro-Gly-Pro extension in Semax confers additional activity beyond the ACTH fragment base: it acts as an enkephalin precursor, producing the tripeptide Pro-Gly-Pro upon cleavage, which itself has receptor activity. This means Semax has multiple pharmacologically active breakdown products, not just a single parent compound effect.

BDNF and NGF induction — the neuroplasticity mechanism

The most extensively studied aspect of Semax's pharmacology is its ability to increase expression of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) in brain tissue. Both neurotrophins support neuronal survival, promote dendritic growth and synaptic density, and are critical for the long-term potentiation (LTP) that underlies learning and memory consolidation.

In rodent models, intranasal Semax produces significant increases in BDNF mRNA in the hippocampus and frontal cortex within hours of administration. The effect is more pronounced in aged animals, where baseline BDNF expression is lower — suggesting that the induction mechanism is more impactful when neurotrophin levels are depleted, as they are in aged brains or following ischaemic injury.

BDNF's relevance to cognitive function is well-established: it is the primary driver of the synaptic strengthening that encodes long-term memories, and its decline is associated with cognitive ageing and neurodegenerative conditions. Compounds that reliably increase BDNF expression in hippocampal and cortical tissue have obvious research interest in the context of cognitive maintenance and neurological recovery.

Monoamine modulation

Semax modulates dopamine and serotonin systems in ways that contribute to its cognitive and mood-related effects. In rodent studies, Semax increases dopamine turnover in the prefrontal cortex — the region critical for executive function, working memory, and goal-directed behaviour. This is consistent with MC4R's role in prefrontal dopaminergic signalling and helps explain the attention-enhancing effects observed in behavioural tasks.

The serotonin system involvement is relevant for the compound's anxiolytic-adjacent profile. Unlike Selank, which primarily targets GABA and enkephalin, Semax appears to modulate serotonergic activity in limbic circuits, contributing to reduced anxiety and improved stress tolerance without direct serotonin reuptake inhibition.

These monoamine effects distinguish Semax from pure nootropics that focus exclusively on acetylcholine or glutamate systems. The combination of MC4R-driven attention enhancement, BDNF-mediated neuroplasticity, and monoamine modulation produces a multi-dimensional cognitive pharmacology that no single-mechanism compound replicates.

Neuroprotection in ischaemic models

Semax's most robust clinical application in Russian research has been in stroke rehabilitation and cerebrovascular recovery. In rodent ischaemic stroke models (middle cerebral artery occlusion), Semax reduces infarct volume, decreases post-ischaemic neuroinflammation, and improves functional recovery relative to controls.

The mechanisms are multiple: BDNF induction reduces apoptosis in the penumbra zone (tissue at risk but not yet dead following stroke), anti-inflammatory effects reduce secondary damage from microglial activation, and improvements in cerebral blood flow through nitric oxide pathway involvement reduce ischaemic extension.

These neuroprotective effects in ischaemia models are what drove the clinical use in Russian stroke rehabilitation. The translation to human protocols for cognitive enhancement in non-clinical populations requires separate evaluation, but the mechanistic foundation for CNS neuroprotection is the same — sustained BDNF induction and anti-inflammatory activity.

Research-grade Semax with full HPLC purity and mass spectrometry verification is available through RetaLABS for preclinical research applications.

Semax's mechanistic story spans acute MC4R-driven cognitive effects, BDNF/NGF-mediated neuroplastic changes, and monoamine modulation — a multi-mechanism profile that positions it distinctly among research nootropics and one that the neuroprotection data in ischaemia models substantiates at the cellular level.